MedTrace Logo

Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome

NCT02249169 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2022-08-17

No results posted yet for this study

Summary

This longitudinal study is being done to understand mechanisms underlying development of irritable bowel syndrome (IBS) and the role of the gut bacteria in development of symptoms. This information will be used to determine whether temporal changes in gut microbial taxonomy and metabolism are associated with changes in symptom severity in IBS, and if targeted dietary interventions, including prebiotics, can reverse or moderate these changes.

Conditions

  • Irritable Bowel Syndrome

Sponsors & Collaborators

Principal Investigators

  • Purna C. Kashyap, M.B.B.S. · Mayo Clinic

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-19
Primary Completion
2017-02-08
Completion
2017-02-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02249169 on ClinicalTrials.gov